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Keiko Nemoto Murofushi1,2*, Masahiko Oguchi2, Masahiko Gosho3, Takuyo Kozuka2 and Hideyuki Sakurai1Abstract
Background: Radiation-induced bronchiolitis obliterans organizing pneumonia (BOOP) syndrome is a rarely
observed phenomenon characterized by infiltration of the lungs outside of the radiation field, differentiating it from
radiation pneumonitis (RP).The risk factors for radiation-induced BOOP (RT-BOOP) remain unclear and controversial.
We retrospectively analyzed the incidence and risk factors for RT-BOOP associated with radiation therapy (RT) after
breast conserving surgery (BCS) and post-mastectomy radiation therapy (PMRT).
Methods and materials: We analyzed 1,176 breast cancer patients treated with RT after BCS or PMRT between
March 2005 and September2008 at the cancer institute hospital of the Japanese foundation for cancer research.
Chest radiographs were routinely obtained every three to six months for at least 12 months after surgery, as well
as when the patients experienced respiratory symptoms or fever.
Results: RT-BOOP syndrome was diagnosed in 16patients (1.4%), including12BCS patients (1.3%) and four PMRT
patients (1.8%). An older age (≥52 years old) was significantly associated with the incidence of RT-BOOP syndrome
in a univariate analysis (p =0.023). The type of treatment (BCS or PMRT) and irradiated lung volume at 20 Gy (V20)
were not significantly associated with the incidence of RT-BOOP syndrome in the entire patient cohort. In the
multivariate analysis, age and smoking were the significant factor associated with RT-induced BOOP syndrome
(p =0.044 and 0.049, respectively).
Conclusions: RT-BOOP syndrome was a rarity, and the incidence for BCT cases was similar to that for PMRT cases.
The irradiated lung volume was not significantly associated with RT-BOOP syndrome. An older age can predict the
incidence of RT-BOOP syndrome.
Keywords: Breast Cancer, Postoperative radiotherapy, Radiation-induced bronchiolitis obliterans organizing
pneumonia syndrome, Breast-conserving therapy, Post-mastectomy radiation therapyBackground
Radiation therapy (RT) plays an important role in the
management of patients with breast cancer. The major-
ity of patients with early breast cancer have been treated
with breast-conserving treatment (BCT), consisting of
wide excision and postoperative RT. Post-mastectomy
radiation therapy (PMRT) is mainly applied for locally
advanced breast cancer patients with T3 and T4 disease,
or with four or more positive axillary lymph nodes.* Correspondence: keiko.nemoto@jfcr.or.jp
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unless otherwise stated.Recent meta-analyses demonstrated that RT after breast-
conserving surgery (BCS) and PMRT provided absolute
improvements in the local five-year recurrence rate and
the survival rates after 10 years or more [1,2].
Bronchiolitis obliterans organizing pneumonia (BOOP)
is recently recognized the disorder associated with “or-
ganizing pneumonia”. It is mostly idiopathic, and pos-
sibly caused by various etiological factors, including
pulmonary infections, drugs, collagen vascular disease
or RT. The symptoms of BOOP syndrome are cough,
fever, dyspnea, malaise or some combination of these [3].
Radiation-induced BOOP (RT-BOOP) syndrome, which
is commonly seen outside of the radiation fields, isral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ferent from typical radiation pneumonitis (RP) that oc-
curs within the RT field. Recent reports showed that the
incidence of RT-BOOP syndrome in breast cancer pa-
tients after BCT was 1.8-2.9% [4-10]. However, the risk
factors remain unclear and controversial. For RT-BOOP
syndrome of patients treated with PMRT, the available
data is very limited. We retrospectively analyzed 1,176
patients treated with BCT or PMRT, and evaluated the
incidence and risk factors for RT-BOOP syndrome in
the Cancer Institute Hospital of the Japanese Founda-
tion for Cancer Research.
Methods and materials
Patient characteristics
Between March 2005 and September 2008, 1,215 breast
cancer patients underwent RT after BCS or PMRT. We
analyzed 1,176 patients who underwent both surgery
and RT at our institution, had no prior RT to the thorax
that would result in an overlap of RT fields and had under-
gone no cardiovascular, pulmonary or esophageal surgery
within one year of the treatment. The median follow-up
periods were 25.5 months (range, 8.1 to 53.4 months) for
all patients, 26.1 months (range, 8.1to 53.4 months) for
BCT cases and 23.7 months (range, 8.2 to 52.1 months)
for PMRT cases. The characteristics of the 1,176 patients
are shown in Table 1. All patients were females, and 19
patients were irradiated for bilateral breast cancer. The
majority of the patients were in clinical stage I (n = 477) or
II (n =415), therefore, 948 patients were classified into the
BCT group, while 228 patients were in the PMRT group.Table 1 Patient characteristics (n = 1176)
Age(y), median (range) 52 (19-93)
Breast site (right/left/bilateral) 584/573/19
Collagen vascular disease (yes/no) 2/1174
Smoking (yes/no/unknown) 201/973/2
Alcohol (yes/no/unknown) 439/735/2
Allergy (yes/no/unknown) Clinical stage (n = 1195 lesion) 400/775/1
0 163
I 477
IIA/IIB 270/145
IIIA/IIIB/IIIC 48/32/49
IV 2
ocult 4
Ipsilateral breast tumor recurrence 5
Histologictype (n = 1195lesion) Noninvasive ductal
carcinoma
169
Invasive ductal carcinoma 929
Others 97This study was approved with the ethical review commit-
tee of department.
Treatment strategy for breast cancer
The treatment protocols for breast cancer in our institute
are shown in Figure 1. In most cases of BCT (Figure 1a),
wide excision was initially performed. The primary lesions
were extracted by vertical resection from the skin to the
fascia of the greater pectoral muscle. We have in-house
clinical study of BCT without XRT for 20 years or more,
and Nishimura reported the preliminary results that local
recurrence of non RT-BCT patients with completely nega-
tive margin was 3.2% [11]. Patients with massive positive
margins were treated with additional re-resection of the
conserved breast, and all of those patients received RT
regardless of the marginal status. In patients with T2N1
or more advanced stage disease were treated with neo-
adjuvant chemotherapy, and also received RT regardless
of whether the margins were positive or negative. The
entire breast was irradiated with 4 or 6 MV photon
using opposing tangential fields. Electron beam boost
was performed for most patients. Patients with positive
margins or and the cases treated with neoadjuvant
chemotherapy, but the patients who exhibited a patho-
logical complete response to chemotherapy did not re-
ceive the electron beam boost. Cases with four or more
positive lymph nodes underwent radiation treatments
for both the entire breast and the supra/infraclavicular
lymph node lesions.
The indications for PMRT (Figure1b) were: [1] four
or more pathologically positive axillary lymph nodes,
[2] positive ipsilateral supraclavicular lymph nodes, [3]
T4 or [4] margin positive disease. The internal mam-
mary chain (IMC) was irradiated if the patient had ten
or more positive lymph nodes, or if four or more posi-
tive lymph nodes and the tumor were located on the
inner part of the breast. An electron beam boost was
performed for the cases at high risk of chest-wall recur-
rence, including those with positive margins and/or
massive skin invasion, or the cases with unresected
positive lymph nodes. The treatment fields were set up
with simulators and/or a RT computed tomography plan-
ning system (Eclipse, Varian Medical Systems, PaloAlto,
CA and Render-Plan, Elekta Oncology Systems, Inc, Nor-
cross, GA). The lung volume irradiated at 20 Gy (V20)
was calculated using dose-volume histogram.
The details of the radiotherapy are shown in Table 2.
In the BCT group, the majority of patients (70.5%) re-
ceived 60 or 66 Gy in 30 or 33 fractions of X-rays. Most
patients (94.8%) received additional electron beam
boost irradiation. On the other hand, the majority of
PMRT patients (74.1%) were treated with 50 Gy in 25
fractions, and 74.6% of the patients did not receive
boost irradiation. The median lung V20 was 6.2%
Surgery: wide excision or segmental mastectomy
pathology
massive positive margin slightly positive margin completely negative margin
additional re-resection
on their conserved breast
postoperative RT no RT
postoperative RT
neoadjuvant chemotherapy
Surgery
postoperative RT
regardless of positive
or negative margins
BCT case
Surgery: mastectomy
Indications of PMRT
1) ≥4 positive axillary lymph node (LN)
2) positive ipsilateral supraclavicular LN 
3) T4
4) positive margin
PMRT case
b
a
RT: SC+CW ≥10 positive LNs
or 
≥4 positive LNs with the tumor located
on the inner quadrant of the breast
RT: SC+IMC+CW
SC: supraclavicular LN 
IMC: internal mammary chain
CW: chest wall
Figure 1 The treatment protocols for patients with breast cancer for breast-conserving therapy (a) and post-mastectomy radiation therapy (b).
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dian lung V20 was 13.7% (range, 2.3 to 24.7%) in the
PMRT group.
The details of the pharmaceutical therapy are shown
in Table 3. Endocrine therapy was administered to 67.7%
of all patients. During radiation therapy, concurrent endo-
crine therapy was prescribed for most patients. Approxi-
mately half of the patients (51.6%) received neoadjuvantand/or adjuvant chemotherapy. No patients received
chemotherapy concurrent with RT. Trastuzumab was
administered to only 68 patients.
Definition of radiation-induced BOOP syndrome
RT-BOOP syndrome was diagnosed based on the criteria
proposed by Crestani et al. [12], which included: [1] a his-
tory of radiation therapy to the breast within the past
Table 2 Radiation therapy details
BCT (n = 948) PMRT (n = 228)
Total dose and fractions*
50 Gy in 25 fractions 42 169
50 Gy in 20 fractions 100 0
53.2 Gy in 20 fractions 114 0
60 Gy in 30 fractions 468 51
66 Gy in 33 fractions 200 4
70 Gy in 35 fractions 0 2
Others 43 2
Boost to the tumor bed
(yes/no)*
917 (95%)/50 (5%) 58 (25%)/170 (75%)
Lung V20 (%), median (range) 6.2% (0.2-31.8) 13.7% (2.3-24.7)
Overall radiation therapy time
(days), median (range)
42 days (21-65) 36 days (28-66)
*The 19 patients of 948 had bilateral breast cancers simultaneously and were
treated with BCT, as a result, the treatment planning of 967 patients
were evaluated.
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ing for at least two weeks, [3] radiographic lung infiltrates
outside the radiation port, [4] no evidence of a specific
cause. We have routinely followed the patients routinely
at three, six and 12 months after radiation therapy. Chest
X-rays were routinely taken every three to six months
for at least 12 months after surgery. In addition when
patients had developed consistent respiratory symptoms
or fever, additional chest X-rays was examined. In theTable 3 Drug therapy details (n = 1176)
Endocrine therapy (yes/no) 796 (68%)/380 (32%)
Tamoxifen + LHRH agonist 106
Tamoxifen 289
Anastrozole 351
Letrozole 35
Exemestane 13
Others 2
Concurrent endocrine therapy (yes/no) 765 (96%)/31 (4%)
Chemotherapy (yes/no) 607 (52%)/569 (48%)
Preoperative 231
Postoperative 342
Pre and postoperative 32
unknown 2
Anthracycline + Taxiane-based regimen 471
Anthracycline-based regimen 119
Taxiane-based regimen 10
Others 7
Trastuzumab (yes/no) 68 (6%)/1108 (94%)case with general and/or respiratory symptoms lasting
two or more weeks and lung infiltrative findings were
observed on chest X-rays, computed tomography (CT)
scanning was performed.
Statistical analyses
Results are presented as number (proportion) of patients
for categorical variables. The incidence of RT-BOOP
syndrome was analyzed by use of Fisher’s exact test as a
univariate analysis. In addition, the incidence was assessed
by using a multivariate logistic regression model to iden-
tify risk factors of RT-BOOT syndrome. The risk factors
in the multivariate model were set based on the result of
the univariate analysis. The factors with p < 0.15 in the
univariate analysis for all patients or for the BCT cases
were included in a multivariate model. In the univariate
analysis, age was categorized in less than 52 years (the me-
dian) and 52 years or above. Lung V20 was also catego-
rized in 5% intervals as 0-4.9, 5.0-9.9, 10.0-14.9, 15.0-19.9,
20.0-24.9, 25.0-29.9 and 30.0-34.9%. In the multivariate lo-
gistic regression analysis, the age variable was treated as a
continuous variable. The statistical analyses were per-
formed using the SPSS Base System software program
(SPSS, Chicago, IL) and the SAS software version 9.4 (SAS
Institute, Cary, NC). A value of p < 0.05 was considered to
be statistically significant.
Results
A typical case of RT-BOOP syndrome is illustrated in
Figure 2. The details of clinical characteristics the pa-
tients with RT-BOOP syndrome are shown in Table 4.
Sixteen patients (1.4%) of all developed RT-BOOP syn-
drome. Twelve of all (1.3%) were treated with BCT, and
four of all (1.8%) were treated with PMRT. The median
age of these 16 patients was 57 years (range, 43 to
79 years). Thirteen (81%) of them received endocrine
therapy; tamoxifen (TAM) was administered to five
patients, anastrozole (ANA) to seven and both TAM
and a LHRH agonist were administered to one. Six
(37%) of these patients received chemotherapy. The me-
dian lungV20 was 6.4% (range, 4.0 to 17.7%) for the 16
patients with RT-BOOP, 6.0% (range, 4.0 to 6.0%) for
the twelve BCT cases and 14.5% (range, 4.8 to 17.7%)
for the four PMRT cases. Figure 3 shows the actual V20
data for all of the patients. Although the V20 in the
PMRT cases was higher than that in the BCT cases, no
correlation was found between theV20 and incidence of
RT-BOOP. On the other hand, eighteen patients (1.5%)
of all developed grade 2 RP. Thirteen of them were
treated with BCT (1.4%), and five of them were treated
with PMRT (2.2%). No grade 3 or more RP was seen in
all cases.
The median period from completion of RT to the
diagnosis of RT-BOOP syndrome was 4.9 months (range,
4 months after RT 6 months after 6.5 months after 9.5 months after
Figure 2 55-year-old patient received irradiation in the whole left breast (50 Gy/25 fractions) with an electron boost (10 Gy/5 fractions) to the
partial breast. The lung V20 was 6.0%. Four months after RT following breast-conserving surgery, a severe cough, fever and decreased oxygen
saturation measured by a pulseoximeter (SpO2; 88% at room air) were observed. Pulmonary lesions outside the irradiated field were observed
on chest radiographs, which were located in the bilateral lungs on CT. Prednisolone was started at 30 mg/day based on a diagnosis of BOOP
syndrome. The prednisolone was gradually tapered off, because the symptoms and pulmonary lesions were improved. However, the pulmonary
lesions appeared again at 6.5 months after RT without any symptoms. Prednisolone was again administered until 7.5 months after RT. Although
the pulmonary lesions appeared again at 9.5 months after RT, there were no symptoms.
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nosis of RT-BOOP syndrome to the last follow-up for
all cases was 19.3 months (range, 3.9 to 39.9 months).
The pulmonary findings of RT-BOOP disappeared in
14 of the patients during observation. The other two
had been repeatedly relapsed BOOP syndrome over the
years. Figure 2 shows the typical pulmonary findings of
RT-BOOP marching both lungs on CT over 9 months.
Steroids were administered to both of these patients,
with durations of administration of seven days and
3.6 months.
Table 5 shows the factors associated with RT-BOOP
syndrome for all patients, BCT cases, and PMRT cases
as evaluated with a univariate analysis. For all patients,
age was significantly associated with RT-BOOP syn-
drome (p = 0.023). There was no significant difference
in the rate related to the use of endocrine therapy, but
the incidence of RT-BOOP syndrome in the patients
who received endocrine therapy (1.6%) was higher than
the incidence of the patients without endocrine therapy
(0.8%). The type of treatment (BCT or PMRT) and
lungV20 were not significantly associated with the de-
velopment of RT-BOOP syndrome. For the BCT cases
evaluated with a univariate analysis, age was signifi-
cantly associated with the incidence of RT-BOOPsyndrome (p = 0.039). Smoking, chemotherapy and endo-
crine therapy were somewhat associated with RT-BOOP
syndrome, though there was not statistically significant as-
sociation (p = 0.10, 0.14 and 0.12, respectively). The lung
V20 was not significantly associated with RT-BOOP
syndrome. For the PMRT cases, none of the factors were
significantly associated with RT-BOOP syndrome be-
cause the number of patients with RT-BOOP syndrome
was too small and the statistical power was not enough
to detect the association.
In the multivariate analysis, age associated with the inci-
dence of RT-BOOP syndrome for all patients (p = 0.044),
whereas age was a borderline significant risk factor for the
incidence in BCT cases (p = 0.098) (Table 6). The inci-
dence of RT-BOOP syndrome for smoking patients was
higher than that for non-smoking patients (p = 0.049 for
all patients, p = 0.033 for BCT cases). The incidence of
RT-BOOT syndrome for the PMRT cases was not ana-
lyzed by using the multivariate logistic regression model
because the number of patients with RT-BOOP syndrome
was too small for the statistical analysis (n = 4).
Discussion
The prognosis of breast cancer patients has improved
over the past few decades [12]. RT plays an important
Table 4 Details of the patients with BOOP syndrome (n = 16)
Patient no. Endocrine therapy CT Lung V20(%) Time after RT (mo) Symptoms Treatment
1 BCT TAM - 7.9 7.6 cough antitussive,
LHRH-agonist antibiotic
2 BCT TAM - 6.0 4.0 cough, pyrexia, steroid,
decreased SpO2 antibiotic
3 BCT TAM - 5.0 5.3 cough, pyrexia, antitussive,
fatigue antibiotic
4 BCT TAM - 8.6 5.1 cough, pyrexia antitussive,
antibiotic
5 BCT TAM - 8.1 2.3 cough antitussive,
steroid
6 BCT ANA - 4.4 5.0 cough, fatuigue antibiotic
7 BCT ANA - 6.0 4.7 cough antitussive,
antibiotic
8 BCT ANA - 5.1 3.0 cough, pyrexia antitussive
9 BCT ANA - 9.0 4.5 cough antitussive,
antibiotic
10 BCT ANA - 4.8 3.1 cough, fatigue antitussive,
antibiotic
11 BCT ANA AC 6.8 8.6 cough antitussive
PAC
12 BCT - CAF 5.6 6.0 cough antibiotic
13 PMRT TAM CAF 17.7 3.3 cough, pyrexia antitussive,
PAC antibiotic
14 PMRT ANA CAF 13.4 7.4 cough antitussive,
PAC antibiotic
15 PMRT - CAF 15.6 3.9 cough, pyrexia antibiotic
PAC
16 PMRT - CAF 22.0 5.3 cough, pyrexia, antitussive
PAC fatigue
Abbreviations
CT Chemotherapy.
TAM Tamoxifen.
ANA Anastrozole
AC Doxorubicin, Cyclophosphamide.
PAC Paclitaxel.
CAF Cyclophosphamide, Doxorubicin and Fluorouracil.
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and several studies showed a reduction of locoregional
recurrence in breast cancer patients receiving postopera-
tive irradiation [13]. In our previous study, the ipsilateral
breast tumor recurrence rate after postoperative RT was
only 1.6% [11]. Although the adverse events induced by
postoperative RT for patients with breast cancer are gen-
erally mild, RT-BOOP syndrome does rarely occur, and
can threaten the quality of life (QOL) for patients. It is
necessary early identifying and treating the symptomsassociated with RT-BOOP, such as cough, fever, dyspnea
and/or fatigue and the QOL should be improved.
Radiographic lung infiltration of RP occurs inside the
irradiated area of the lungs [14], and the percentage of
the total lung volume exceeding 20 Gy (V20) can pre-
dict the development of Grade 2 or greater RP [15]. A
recent study reported that radiation techniques deliver-
ing doses of 10 to 15 Gy to large lung volumes were sig-
nificantly correlated with the incidence of RP [16]. RP is
recognized as a direct lung injury caused by irradiation,
Lu
ng
 V
20
 (
%
)
BCT PMRT
Figure 3 The lung V20 of all patients according to the type of treatment. The cases that developed radiation-induced BOOP are shown by red circles.
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lung injury related to an autoimmune process [4,17].
We estimated an association between lung V20 and the
development of the BOOP syndrome. V10 and V5 are
not clearly different from V20 in treatment planning
with opposing tangential fields. In this study we evaluate
lung V20 among the irradiated lung parameters.
The incidence of RT-BOOP syndrome after BCT was
reported to be 1.2 -2.9% (Table 7) [4-10]. However, it
was unclear whether there was an association between
the irradiated lung dose and volume and the incidence
of RT-BOOP. Kubo et al. reported that the central lung
distance (CLD) >1.8 cm, which was considered to be cor-
related with the irradiated lung volume, was significantly
associated with RT-BOOP syndrome [10]. Katayama et al.
reported that a CLD ≥ 3 cm was not significantly associ-
ated with RT-BOOP [7]. In our study, which investi-
gated over 1,000 patients at a single institute, the lung
V20 was not a significant factor predicting the develop-
ment of RT-BOOP.
Some physicians have expressed concern about the po-
tential for an increased incidence of RT-BOOP in PMRT
group, who have a larger irradiated lung volume than
BCT cases. In our study, the median lung V20 was 6.2%
(0.2-31.8%) for BCT cases, while it was 13.7% (2.3-24.7%)
for PMRT cases. However, the type of treatment (BCT/
PMRT) was not significantly associated with the incidence
of RT-BOOP syndrome (p = 0.53), even though the PMRTcases received radiation to a wider lung area than BCT
cases. Additionally, several previous studies surveyed the
incidence of RT-BOOP syndrome for BCT cases, but not
for PMRT cases. In the present study, we also clarified that
the incidence of RT-BOOP in PMRT cases, which was
1.8%, was similar to that in BCT cases. Based on our long-
term follow up study, we concluded that the irradiated
lung volume does not predict the development of RT-
BOOP syndrome.
The patient age (≥52 years) was significantly associated
with RT-BOOP syndrome for all 1,176 patients and for
the BCT cases in the univariate analyses, however it was
not a significant risk factor for PMRT cases in this study.
In the multivariate analysis, age associated with the inci-
dence of RT-BOOP syndrome for all patients (p = 0.044).
The number of PMRT cases was smaller, it is necessary
to analyze the larger number of PMRT cases for assess-
ment whether age was a significant risk or not. But three
of the four PMRT cases with RT-BOOP syndrome were
more than 52 years old. We therefore conclude that age
is the most important factor for predicting the develop-
ment of RT-BOOP in breast cancer patients.
Endocrine therapy, including TAM and aromatase in-
hibitors, reduced the recurrence rate and improved the
survival for the patients with endocrine-responsive breast
cancer [18,19]. It has been reported that the concurrent
use of TAM and RT increased the risk of grade 2 or
greater subcutaneous fibrosis [20] and lung fibrosis [21].
Table 5 Univariate analysis of factors associated with RT-BOOT symdrome
ALL (n = 1176) BCT (n = 948) PMRT (n = 228)
Parameter Level n (%) Incidence
of BOOP
syndrome,
n (%)
p n (%) Incidence
of BOOP
syndrome,
n (%)
p n (%) Incidence
of BOOP
syndrome,
n (%)
p
Age <52y* 559 (48) 3 (0.5) 0.023 457 (48) 2 (0.4) 0.039 102 (45) 1 (1.0) 0.63
>-52y 617 (52) 13 (2.1) 491 (52) 10 (2.0) 126 (55) 3 (2.4)
OneSide One side 1157 (98) 16 (1.4) 1.00 929 (98) 12 (1.3) 1.00 228 (100) 4 (1.8) -
Bilateral 19 (2) 0 (0.0) 19 (2) 0 (0.0) 0 (0) 0 (0)
Allergy Yes 400 (34) 6 (1.5) 0.79 328 (35) 5 (1.5) 0.76 72 (32) 1 (1.4) 1.00
No 775 (66) 10 (1.3) 619 (65) 7 (1.1) 156 (68) 3 (1.9)
Unkonwn 1 (0) 0 (0.0) 1 (0) 0 (0.0) 0 (0) 0 (0.0)
Smoking Yes 201 (17) 5 (2.5) 0.17 147 (16) 4 (2.7) 0.10 54 (24) 1 (1.9) 1.00
No 973 (83) 11 (1.1) 800 (84) 8 (1.0) 173 (76) 3 (1.7)
Unkonwn 2 (0) 0 (0.0) 1 (0) 0 (0.0) 1 (0) 0 (0.0)
Chemotherapy Yes 607 (52) 6 (1.0) 0.32 389 (41) 2 (0.5) 0.14 218 (96) 4 (1.8) 1.00
No 569 (48) 10 (1.8) 559 (59) 10 (1.8) 10 (4) 0 (0.0)
ET Yes 796 (68) 13 (1.6) 0.29 635 (67) 11 (1.7) 0.12 161 (71) 2 (1.2) 0.58
No 380 (32) 3 (0.8) 313 (33) 1 (0.3) 67 (29) 2 (3.0)
RT Yes 765 (96) 13 (1.7) 1.00 614 (97) 11 (1.8) 1.00 151 (94) 2 (1.3) 1.00
No 31 (4) 0 (0.0) 21 (3) 0 (0.0) 10 (6) 0 (0.0)
Trastuzumab Yes 68 (6) 2 (2.9) 0.24 35 (4) 0 (0.0) 1.00 33 (14) 2 (6.1) 0.10
No 1108 (94) 14 (1.3) 913 (96) 12 (1.3) 195 (86) 2 (1.0)
Treatment BCT 948 (81) 12 (1.3) 0.53 - - - - - -
PMRT 228 (19) 4 (1.8)
Boost Yes 963 (82) 13 (1.3) 1.00 902 (95) 12 (1.3) 1.00 61 (27) 1 (1.6) 1.00
No 213 (18) 3 (1.4) 46 (5) 0 (0.0) 167 (73) 3 (1.8)
Irradiation to
the regional LNs
Yes 269 (23) 4 (1.5) 0.77 58 (6) 0 (0.0) 1.00 211 (93) 4 (1.9) 1.00
No 907 (77) 12 (1.3) 890 (94) 12 (1.3) 17 (7) 0 (0.0)
Lung V20 0-4.9% 280 (24) 2 (0.7) 0.19 274 (29) 2 (0.7) 0.62 6 (3) 0 (0.0) 0.32
5.0-9.9% 620 (53) 10 (1.6) 586 (62) 10 (1.7) 34 (15) 0 (0.0)
10.0-14.9% 166 (14) 1 (0.6) 62 (7) 0 (0.0) 104 (46) 1 (1.0)
15.0-19.9% 93 (8) 2 (2.2) 22 (2) 0 (0.0) 71 (31) 2 (2.8)
20.0-24.9% 14 (1) 1 (7.1) 2 (0) 0 (0.0) 12 (5) 1 (8.3)
25.0-29.9% 0 (0) 0 (0.0) 0 (0) 0 (0.0) 0 (0) 0 (0.0)
30.0-34.9% 1 (0) 0 (0.0) 1 (0) 0 (0.0) 0 (0) 0 (0.0)
Unkonwn 2 (0) 0 (0.0) 1 (0) 0 (0.0) 1 (0) 0 (0.0)
P: by Fisher’s exact test.
*: median of age.
Abbreviations
BOOP Bronchiolitis obliterans organizing pneumonia.
ET Endocrine therapy.
RT Radiation therapy.
LNs Lymph nodes.
BCT Breast conserving therapy.
PMRT Postmastectomy radiation therapy.
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(ET) increased the risk of RT-BOOP syndrome. ET was
not significantly associated with RT-BOOP syndrome inour study (p = 0.25). In our institution, since concurrent
ET and RT were conducted for most of the patients, it is
unknown whether the concurrent or sequential use of ET
Table 6 Multivariate logistic regression analysis for RT-BOOP syndrome
ALL BCT
Parameter Level OR (95% CI) p OR (95% CI) p
Age 10 y increased 1.58 (1.01, 2.48) 0.044 1.54 (0.92, 2.57) 0.098
Smoking Yes/No 3.09 (1.01, 9.48) 0.049 4.12 (1.12, 15.11) 0.033
ET Yes/No 2.09 (0.59, 7.44) 0.25 5.50 (0.70, 43.29) 0.11
Chemotherapy Yes/No 0.56 (0.20, 1.60) 0.28 0.28 (0.06, 1.32) 0.11
OR odds ratio.
CI confidence interval.
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However, there were no differences in the incidence be-
tween patients taking TAM and other hormone treat-
ments, including aromatase inhibitors, in our study.
Chemotherapy was not significantly associated with
RT-BOOP syndrome in this study (p = 0.28). 10 ofthe12
patients with RT-BOOP syndrome had not received
chemotherapy. Since one of the suggested mechanisms
underlying the RT-BOOP included hypersensitivity or
an allergic response, it is possible that chemotherapy
may reduce these immune responses. However, it is ne-
cessary to evaluate more cases to clarify the true correl-
ation between chemotherapy and BOOP.
In this study, trastuzumab was not significantly asso-
ciated with RT-BOOP. However, only 68 of the 1,176
patients were administered trastuzumab, so it will be
necessary to analyze the correlation between trastuzu-
mab and RT-BOOP in more patients receiving trastuzu-
mab. The concurrent use of trastuzumab and RT for
BCT patients was previously reported not to be associ-
ated with an increased rate of acute adverse events, in-
cluding RP [22], and further follow-up will be necessary
to evaluate the impact on late adverse events.
It has been reported that smoking depressed the fre-
quency of RP in breast cancer and esophagus cancer
patients [23]. Bjermer suggested that ongoing smoking
during RT decreased an inflammatory response in the
lung tissue induced by radiation [24]. The RT-BOOPTable 7 Reports of radiation induced BOOP syndrome
Authors Year Investigation Materials N
Takigawaetal [4] 2000 single institute BCT 15
Miwaetal [5] 2004 single institute BCT 20
Ogoetal [6] 2008 multi-institute BCT 20
Katayamaetal [7] 2009 multi-institute BCT 70
Kuboetal [8] 2009 multi-institute BCT 41
Ogoetal [9] 2010 single institute BCT 61
Oieetal [10] 2013 single institute BCT 42
Thisstudy 2014 single institute BCT and PMRT 11syndrome is considered to have different mechanism
from occurrence of RP, although immune response may
play some role for both pulmonary reaction.
In this study, smoking was not significantly associ-
ated with RT-BOOP syndrome for all cases, BCT cases
and PMRT cases in a univariate analysis (p = 0.17, 0.10
and 1.00, respectively). In the multivariate analysis,
however, the incidence of RT-BOOP syndrome for
smoking patients was higher than that for non-smoking
patients (p = 0.049 for all patients, p = 0.033 for BCT
cases). The association between RT-BOOP syndrome
and smoking was not evaluated in the previous data. In
this study, smoking group included several smoking
habits including heavy and former smoker, however,
very few current smoker during RT were included. In
order to explain the association between smoking habit
and RT-BOOP syndrome, we need further study using
large data base.
In conclusion, the incidence of RT-BOOP syndrome
was 1.4% for all 1,176 patients, and there were no signifi-
cant differences between the BCT cases (1.3%) and for
PMRT cases (1.8%). The lung V20 was not correlated with
the development of RT-BOOP. The older age is the most
important factor for the prediction of RT-BOOP syndrome
in breast cancer patients who receive radiation therapy.
We should pay attention to old breast cancer patients
treated with postoperative RT to have the early diagnose of
RT-BOOP syndrome.umber of patient Incidence (%) Related factor
7 2.5 Immunologic reaction
6 2.4 not evaluated
56 1.8 no factor was reported
2 2.3 age >50, concurrent
3 2.9 endocrine therapy irradiated
lung volume
6 1.9 no factor was reported
8 1.2 radiation pneumonitis
76 1.4 older age
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